Conditions: Hypercholesterolemia Dyslipidemia
Keywords: PF-04950615 RN316
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 93
Healthy volunteers: no

Brief summary:
This study will investigate the effect of PF-04950615, a new investigational lipid lowering agent, on LDL-C and other lipids.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None

Interventions: intervention 1: Placebo intervention 2: Statin intervention 3: PF-04950615 (RN316) intervention 4: Statin intervention 5: PF-04950615 (RN316) intervention 6: Statin intervention 7: PF-04950615 (RN316) intervention 8: Satin intervention 9: PF-04950615 (RN316) intervention 10: Statin
Intervention descriptions: intervention 1: Intravenous placebo monthly during treatment phase. intervention 2: Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET. intervention 3: Intravenous 10mg/mL based on weight monthly during treatment phase. intervention 4: Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET. intervention 5: Intravenous 10mg/mL based on weight monthly during treatment phase. intervention 6: Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET. intervention 7: Intravenous 10mg/mL based on weight monthly during treatment phase. intervention 8: Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET. intervention 9: Intravenous 10mg/mL based on weight monthly during treatment phase. intervention 10: Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.

Protocol document: